Stock LAURUSLABS LAURUS LABS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Laurus Labs Limited

Equities

LAURUSLABS

INE947Q01028

Delayed NSE India S.E.
Other stock markets
 05:38:57 14/05/2024 BST 		5-day change 1st Jan Change
429.4 INR -0.82% Intraday chart for Laurus Labs Limited +0.19% +0.01%
04-25 Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024
04-25 Laurus Labs' Consolidated Profit Falls in Fiscal Q4 MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • With an expected P/E ratio at 121.6 and 56.26 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
LAURUS LABS LIMITED Stock Laurus Labs Limited
+0.01% 2.79B
C-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 682B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.34% 586B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.07% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.21% 240B
B+
NOVARTIS AG Stock Novartis AG
+9.66% 209B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.83% 203B
A+
AMGEN INC. Stock Amgen Inc.
+7.09% 165B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LAURUSLABS Stock
  4. Ratings Laurus Labs Limited